Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
96820301 | 9682030 | 1 | I | 20131106 | 20131111 | 20131111 | EXP | US-MPIJNJ-2013MPI000869 | MILLENNIUM | 56.00 | YR | M | Y | 92.00000 | KG | 20131111 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
96820301 | 9682030 | 1 | PS | VELCADE | 1 | SUBCUTANEOUS | 2.85 MG, ON DAYS 1, 4, 8 AND 11 | D | 21602 | 2.85 | MG | INJECTION | |||||||
96820301 | 9682030 | 2 | SS | CYTOXAN | 1 | INTRAVENOUS | 450 MG, UNK | D | 0 | 450 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
96820301 | 9682030 | 1 | Plasma cell myeloma |
96820301 | 9682030 | 2 | Plasma cell myeloma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
96820301 | 9682030 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
96820301 | 9682030 | Constipation | |
96820301 | 9682030 | Dehydration | |
96820301 | 9682030 | Fall | |
96820301 | 9682030 | Orthostatic hypotension |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
96820301 | 9682030 | 1 | 20130927 | 0 | ||
96820301 | 9682030 | 2 | 20130927 | 0 |